Base de dados : MEDLINE
Pesquisa : D01.524.550 [Categoria DeCS]
Referências encontradas : 4534 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 454 ir para página                         

  1 / 4534 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29272274
[Au] Autor:De Silva DA; Proctor L; von Dadelszen P; McCoach M; Lee T; Magee LA; Canadian Perinatal Network (CPN) Collaborative Group
[Ad] Endereço:Department of Obstetrics & Gynaecology, University of British Columbia, Vancouver, Canada.
[Ti] Título:Determinants of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia.
[So] Source:PLoS One;12(12):e0189966, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Magnesium sulphate is recommended by international guidelines to prevent eclampsia among women with pre-eclampsia, especially when it is severe, but fewer than 70% of such women receive magnesium sulphate. We aimed to identify variables that prompt Canadian physicians to administer magnesium sulphate to women with pre-eclampsia. METHODS: Data were used from the Canadian Perinatal Network (2005-11) of women hospitalized at <29 weeks' who were thought to be at high risk of delivery due to pre-eclampsia (using broad Canadian definition). Unadjusted analyses of relative risks were estimated directly and population attributable risk percent (PAR%) calculated to identify variables associated with magnesium sulphate use. A multivariable model was created and a generalized estimating equation was used to estimate the adjusted RR that explained magnesium sulphate use in pre-eclampsia. The adjusted PAR% was estimated by bootstrapping. RESULTS: Of 631 women with pre-eclampsia, 174 (30.1%) had severe pre-eclampsia, of whom 131 (75.3%) received magnesium sulphate. 457 (69.9%) women had non-severe pre-eclamspia, of whom 291 (63.7%) received magnesium sulphate. Use of magnesium sulphate among women with pre-eclampsia could be attributed to the following clinical factors (PAR%): delivery for 'adverse conditions' (48.7%), severe hypertension (21.9%), receipt of antenatal corticosteroids (20.0%), maternal transport prior to delivery (9.9%), heavy proteinuria (7.8%), and interventionist care (3.4%). CONCLUSIONS: Clinicians are more likely to administer magnesium sulphate for eclampsia prophylaxis in the presence of more severe maternal clinical features, in addition to concomitant antenatal corticosteroid administration, and shorter admission to delivery periods related to transport from another institution or plans for interventionist care.
[Mh] Termos MeSH primário: Sulfato de Magnésio/uso terapêutico
Pré-Eclâmpsia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Pré-Eclâmpsia/fisiopatologia
Gravidez
Índice de Gravidade de Doença
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
7487-88-9 (Magnesium Sulfate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171223
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189966


  2 / 4534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29182799
[Au] Autor:Knightly R; Milan SJ; Hughes R; Knopp-Sihota JA; Rowe BH; Normansell R; Powell C
[Ad] Endereço:PHRI, St George's, University of London, London, UK.
[Ti] Título:Inhaled magnesium sulfate in the treatment of acute asthma.
[So] Source:Cochrane Database Syst Rev;11:CD003898, 2017 11 28.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Asthma exacerbations can be frequent and range in severity from mild to life-threatening. The use of magnesium sulfate (MgSO4) is one of numerous treatment options available during acute exacerbations. While the efficacy of intravenous MgSO4 has been demonstrated, the role of inhaled MgSO4 is less clear. OBJECTIVES: To determine the efficacy and safety of inhaled MgSO4 administered in acute asthma. SPECIFIC AIMS: to quantify the effects of inhaled MgSO4 I) in addition to combination treatment with inhaled ß2-agonist and ipratropium bromide; ii) in addition to inhaled ß2-agonist; and iii) in comparison to inhaled ß2-agonist. SEARCH METHODS: We identified randomised controlled trials (RCTs) from the Cochrane Airways Group register of trials and online trials registries in September 2017. We supplemented these with searches of the reference lists of published studies and by contact with trialists. SELECTION CRITERIA: RCTs including adults or children with acute asthma were eligible for inclusion in the review. We included studies if patients were treated with nebulised MgSO4 alone or in combination with ß2-agonist or ipratropium bromide or both, and were compared with the same co-intervention alone or inactive control. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial selection, data extraction and risk of bias. We made efforts to collect missing data from authors. We present results, with their 95% confidence intervals (CIs), as mean differences (MDs) or standardised mean differences (SMDs) for pulmonary function, clinical severity scores and vital signs; and risk ratios (RRs) for hospital admission. We used risk differences (RDs) to analyse adverse events because events were rare. MAIN RESULTS: Twenty-five trials (43 references) of varying methodological quality were eligible; they included 2907 randomised patients (2777 patients completed). Nine of the 25 included studies involved adults; four included adult and paediatric patients; eight studies enrolled paediatric patients; and in the remaining four studies the age of participants was not stated. The design, definitions, intervention and outcomes were different in all 25 studies; this heterogeneity made direct comparisons difficult. The quality of the evidence presented ranged from high to very low, with most outcomes graded as low or very low. This was largely due to concerns about the methodological quality of the included studies and imprecision in the pooled effect estimates. Inhaled magnesium sulfate in addition to inhaled ß2-agonist and ipratropiumWe included seven studies in this comparison. Although some individual studies reported improvement in lung function indices favouring the intervention group, results were inconsistent overall and the largest study reporting this outcome found no between-group difference at 60 minutes (MD -0.3 % predicted peak expiratory flow rate (PEFR), 95% CI -2.71% to 2.11%). Admissions to hospital at initial presentation may be reduced by the addition of inhaled magnesium sulfate (RR 0.95, 95% CI 0.91 to 1.00; participants = 1308; studies = 4; I² = 52%) but no difference was detected for re-admissions or escalation of care to ITU/HDU. Serious adverse events during admission were rare. There was no difference between groups for all adverse events during admission (RD 0.01, 95% CI -0.03 to 0.05; participants = 1197; studies = 2). Inhaled magnesium sulfate in addition to inhaled ß2-agonistWe included 13 studies in this comparison. Although some individual studies reported improvement in lung function indices favouring the intervention group, none of the pooled results showed a conclusive benefit as measured by FEV1 or PEFR. Pooled results for hospital admission showed a point estimate that favoured the combination of MgSO4 and ß2-agonist, but the confidence interval includes the possibility of admissions increasing in the intervention group (RR 0.78, 95% CI 0.52 to 1.15; participants = 375; studies = 6; I² = 0%). There were no serious adverse events reported by any of the included studies and no between-group difference for all adverse events (RD -0.01, 95% CI -0.05 to 0.03; participants = 694; studies = 5). Inhaled magnesium sulfate versus inhaled ß2-agonistWe included four studies in this comparison. The evidence for the efficacy of ß2-agonists in acute asthma is well-established and therefore this could be considered a historical comparison. Two studies reported a benefit of ß2-agonist over MgSO4 alone for PEFR and two studies reported no difference; we did not pool these results. Admissions to hospital were only reported by one small study and events were rare, leading to an uncertain result. No serious adverse events were reported in any of the studies in this comparison; one small study reported mild to moderate adverse events but the result is imprecise. AUTHORS' CONCLUSIONS: Treatment with nebulised MgSO4 may result in modest additional benefits for lung function and hospital admission when added to inhaled ß2-agonists and ipratropium bromide, but our confidence in the evidence is low and there remains substantial uncertainty. The recent large, well-designed trials have generally not demonstrated clinically important benefits. Nebulised MgSO4 does not appear to be associated with an increase in serious adverse events. Individual studies suggest that those with more severe attacks and attacks of shorter duration may experience a greater benefit but further research into subgroups is warranted.Despite including 24 trials in this review update we were unable to pool data for all outcomes of interest and this has limited the strength of the conclusions reached. A core outcomes set for studies in acute asthma is needed. This is particularly important in paediatric studies where measuring lung function at the time of an exacerbation may not be possible. Placebo-controlled trials in patients not responding to standard maximal treatment, including inhaled ß2-agonists and ipratropium bromide and systemic steroids, may help establish if nebulised MgSO4 has a role in acute asthma. However, the accumulating evidence suggests that a substantial benefit may be unlikely.
[Mh] Termos MeSH primário: Agonistas Adrenérgicos beta/administração & dosagem
Antiasmáticos/administração & dosagem
Asma/tratamento farmacológico
Sulfato de Magnésio/administração & dosagem
[Mh] Termos MeSH secundário: Doença Aguda
Administração por Inalação
Agonistas Adrenérgicos beta/efeitos adversos
Adulto
Antiasmáticos/efeitos adversos
Broncodilatadores/administração & dosagem
Criança
Progressão da Doença
Quimioterapia Combinada/métodos
Hospitalização/estatística & dados numéricos
Seres Humanos
Ipratrópio/administração & dosagem
Sulfato de Magnésio/efeitos adversos
Readmissão do Paciente/estatística & dados numéricos
Ensaios Clínicos Controlados Aleatórios como Assunto
Testes de Função Respiratória
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Adrenergic beta-Agonists); 0 (Anti-Asthmatic Agents); 0 (Bronchodilator Agents); 7487-88-9 (Magnesium Sulfate); GR88G0I6UL (Ipratropium)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD003898.pub6


  3 / 4534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29229137
[Au] Autor:Chang YY; Kao MC; Lin JA; Chen TY; Cheng CF; Wong CS; Tzeng IS; Huang CJ
[Ad] Endereço:Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan; Department of Anesthesiology, Taipei Tzu Chi Hospital, Taipei, Taiwan; School of Medicine, Tzu Chi University, Hualien, Taiwan.
[Ti] Título:Effects of MgSO on inhibiting Nod-like receptor protein 3 inflammasome involve decreasing intracellular calcium.
[So] Source:J Surg Res;221:257-265, 2018 Jan.
[Is] ISSN:1095-8673
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Nod-like receptor protein 3 (NLRP3) inflammasome is a multiprotein complex composed of NLRP3, caspase-1, and apoptosis-associated speck-like protein containing a caspase recruitment domain. Activation of NLRP3 inflammasome leads to interleukin-1ß (IL-1ß) upregulation and pyroptosis, a proinflammatory cell death characterized by increased cell size. Of note, calcium signaling is crucial for NLRP3 inflammasome activation. This study elucidated the effects of magnesium sulfate (MgSO ), a potent calcium antagonist, on modulating NLRP3 inflammasome. MATERIALS AND METHODS: THP-1 cells, the human monocytic leukemia cell line, were treated with lipopolysaccharide (LPS, 1 µg/ml) plus nigericin (5 µM) (the LPS + Nig group) and LPS plus nigericin plus MgSO (20 mM) [the LPS + Nig + M(20)] to facilitate investigations. Levels of IL-1ß, pyroptosis, and NLRP3 inflammasome induction as well as intracellular calcium were assayed. RESULTS: IL-1ß concentration of the LPS + Nig + M(20) group was significantly lower than the LPS + Nig group (P = 0.001). Cell size of the LPS + Nig + M(20) group was significantly smaller than the LPS + Nig group (P < 0.001). Level of pyroptotic cell death of the LPS + Nig + M(20) group was significantly lower than the LPS + Nig group (P = 0.004). NLRP3 mRNA and protein concentrations of the LPS + Nig + M(20) group were also significantly lower than the LPS + Nig group (P = 0.021 and P < 0.001). Similarly, apoptosis-associated speck-like protein containing a caspase recruitment domain speck formation ratio and caspase-1 concentration of the LPS + Nig + M(20) group were significantly lower than the LPS + Nig group (both P < 0.001). The change in intracellular calcium level of the LPS + Nig + M(20) group was significantly smaller than the LPS + Nig group (P = 0.001). CONCLUSIONS: MgSO inhibits NLRP3 inflammasome, IL-1ß upregulation, and pyroptosis. The mechanism is consistent with decreased intracellular calcium levels.
[Mh] Termos MeSH primário: Sinalização do Cálcio/efeitos dos fármacos
Inflamassomos/antagonistas & inibidores
Sulfato de Magnésio/farmacologia
Proteína 3 que Contém Domínio de Pirina da Família NLR/metabolismo
Piroptose/efeitos dos fármacos
[Mh] Termos MeSH secundário: Caspase 1/metabolismo
Domínio de Ativação e Recrutamento de Caspases
Seres Humanos
Interleucina-1beta/metabolismo
Células THP-1
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (IL1B protein, human); 0 (Inflammasomes); 0 (Interleukin-1beta); 0 (NLR Family, Pyrin Domain-Containing 3 Protein); 0 (NLRP3 protein, human); 7487-88-9 (Magnesium Sulfate); EC 3.4.22.36 (Caspase 1)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE


  4 / 4534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28459604
[Au] Autor:Mickol RL; Page JL; Schuerger AC
[Ad] Endereço:1 Center for Space and Planetary Sciences, University of Arkansas , Fayetteville, Arkansas.
[Ti] Título:Magnesium Sulfate Salt Solutions and Ices Fail to Protect Serratia liquefaciens from the Biocidal Effects of UV Irradiation under Martian Conditions.
[So] Source:Astrobiology;17(5):401-412, 2017 May.
[Is] ISSN:1557-8070
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The growth of Serratia liquefaciens has been demonstrated under martian conditions of 0.7 kPa (7 mbar), 0°C, and CO -enriched anoxic atmospheres (Schuerger et al., 2013, Astrobiology 13:115-131), but studies into the survivability of cells under hypersaline conditions that are likely to be encountered on Mars are lacking. Serratia liquefaciens cells were suspended in aqueous MgSO solutions, or frozen brines, and exposed to terrestrial (i.e., 101.3 kPa, 24°C, O /N -normal atmosphere) or martian (i.e., 0.7 kPa, -25°C, CO -anoxic atmosphere) conditions to assess the roles of MgSO and UV irradiation on the survival of S. liquefaciens. Four solutions were tested for their capability to attenuate martian UV irradiation in both liquid and frozen forms: sterile deionized water (SDIW), 10 mM PO buffer, 5% MgSO , and 10% MgSO . None of the solutions in either liquid or frozen forms provided enhanced protection against martian UV irradiation. Sixty minutes of UV irradiation reduced cell densities from 2.0 × 10 cells/mL to less than 10 cells/mL for both liquid and frozen solutions. In contrast, 3-4 mm of a Mars analog soil were sufficient to attenuate 100% of UV irradiation. Results suggest that terrestrial microorganisms may not survive on Sun-exposed surfaces on Mars, even if the cells are embedded in frozen martian brines composed of MgSO . However, if dispersed microorganisms can be covered by only a few millimeters of dust or regolith, long-term survival is probable. Key Words: Hypobaria-Mars-Planetary protection-Brines. Astrobiology 17, 401-412.
[Mh] Termos MeSH primário: Serratia liquefaciens/efeitos da radiação
Raios Ultravioleta
[Mh] Termos MeSH secundário: Exobiologia
Meio Ambiente Extraterreno
Gelo
Sulfato de Magnésio
Serratia liquefaciens/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ice); 7487-88-9 (Magnesium Sulfate)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1089/ast.2015.1448


  5 / 4534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28056569
[Au] Autor:Vilchez G; Dai J; Lagos M; Sokol RJ
[Ad] Endereço:a Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology , University of Missouri - Kansas City , Kansas City , MO , USA.
[Ti] Título:Maternal side effects & fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial.
[So] Source:J Matern Fetal Neonatal Med;31(2):178-183, 2018 Jan.
[Is] ISSN:1476-4954
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Evidence supports the need of dose-adjustment of several drugs according to body mass index (BMI) to prevent toxicity in the underweight, and ensure efficacy in obese women. However, for MgSO neuroprotection, the effect of BMI on maternal toxicity and fetal neuroprotection is understudied. We analyze the effect of BMI on maternal/infant outcomes after MgSO . METHODS: Secondary analysis of a clinical trial that studied MgSO neuroprotection. Maternal side effects, magnesium cord levels, and offspring cerebral palsy/death were analyzed along BMI strata using ANOVA and chi-square test. Logistic regression was used to calculate adjusted odds ratios according to the treatment and BMI, using nonobese that received placebo as reference. Interaction analyses were performed to validate differential efficacy of BMI. RESULTS: From 2241 women, more side effects and higher magnesium cord levels were seen in underweight women (p = 0.05). MgSO neuroprotection was effective in the non-obese (p = 0.02), but not in obese women (p = 1.00). In multivariate analyses, MgSO significantly reduced cerebral palsy only in nonobese women. Interaction analyses showed the moderator effect of BMI (p = 0.169). Increasing MgSO dose in obese mothers may ensure neuroprotective efficacy without representing increased maternal risks. Considering costs of studying this association, current analysis may form the basis for reasonable practice.
[Mh] Termos MeSH primário: Paralisia Cerebral/tratamento farmacológico
Paralisia Cerebral/epidemiologia
Sulfato de Magnésio/uso terapêutico
Fármacos Neuroprotetores/uso terapêutico
Obesidade/epidemiologia
Resultado da Gravidez/epidemiologia
[Mh] Termos MeSH secundário: Índice de Massa Corporal
Paralisia Cerebral/prevenção & controle
Feminino
Seres Humanos
Magnésio/sangue
Sulfato de Magnésio/efeitos adversos
Fármacos Neuroprotetores/efeitos adversos
Pré-Eclâmpsia/tratamento farmacológico
Gravidez
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Neuroprotective Agents); 7487-88-9 (Magnesium Sulfate); I38ZP9992A (Magnesium)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE
[do] DOI:10.1080/14767058.2017.1279143


  6 / 4534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28976987
[Au] Autor:Crowther CA; Middleton PF; Voysey M; Askie L; Duley L; Pryde PG; Marret S; Doyle LW; AMICABLE Group
[Ad] Endereço:Liggins Institute, University of Auckland, Auckland, New Zealand.
[Ti] Título:Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis.
[So] Source:PLoS Med;14(10):e1002398, 2017 Oct.
[Is] ISSN:1549-1676
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Babies born preterm are at an increased risk of dying in the first weeks of life, and those who survive have a higher rate of cerebral palsy (CP) compared with babies born at term. The aim of this individual participant data (IPD) meta-analysis (MA) was to assess the effects of antenatal magnesium sulphate, compared with no magnesium treatment, given to women at risk of preterm birth on important maternal and fetal outcomes, including survival free of CP, and whether effects differed by participant or treatment characteristics such as the reason the woman was at risk of preterm birth, why treatment was given, the gestational age at which magnesium sulphate treatment was received, or the dose and timing of the administration of magnesium sulphate. METHODS AND FINDINGS: Trials in which women considered at risk of preterm birth (<37 weeks' gestation) were randomised to magnesium sulphate or control treatment and where neurologic outcomes for the baby were reported were eligible for inclusion. The primary outcomes were infant death or CP and severe maternal outcome potentially related to treatment. Studies were identified based on the Cochrane Pregnancy and Childbirth search strategy using the terms [antenatal or prenatal] and [magnesium] and [preterm or premature or neuroprotection or 'cerebral palsy']. The date of the last search was 28 February 2017. IPD were sought from investigators with eligible trials. Risk of bias was assessed using criteria from the Cochrane Collaboration. For each prespecified outcome, IPD were analysed using a 1-stage approach. All 5 trials identified were included, with 5,493 women and 6,131 babies. Overall, there was no clear effect of magnesium sulphate treatment compared with no treatment on the primary infant composite outcome of death or CP (relative risk [RR] 0.94, 95% confidence interval (CI) 0.85 to 1.05, 6,131 babies, 5 trials, p = 0.07 for heterogeneity of treatment effect across trials). In the prespecified sensitivity analysis restricted to data from the 4 trials in which the intent of treatment was fetal neuroprotection, there was a significant reduction in the risk of death or CP with magnesium sulphate treatment compared with no treatment (RR 0.86, 95% CI 0.75 to 0.99, 4,448 babies, 4 trials), with no significant heterogeneity (p = 0.28). The number needed to treat (NNT) to benefit was 41 women/babies to prevent 1 baby from either dying or having CP. For the primary outcome of severe maternal outcome potentially related to magnesium sulphate treatment, no events were recorded from the 2 trials providing data. When the individual components of the composite infant outcome were assessed, no effect was seen for death overall (RR 1.03, 95% CI 0.91 to 1.17, 6,131 babies, 5 trials) or in the analysis of death using only data from trials with the intent of fetal neuroprotection (RR 0.95, 95% CI 0.80 to 1.13, 4,448 babies, 4 trials). For cerebral palsy in survivors, magnesium sulphate treatment had a strong protective effect in both the overall analysis (RR 0.68, 95% CI 0.54 to 0.87, 4,601 babies, 5 trials, NNT to benefit 46) and the neuroprotective intent analysis (RR 0.68, 95% CI 0.53 to 0.87, 3,988 babies, 4 trials, NNT to benefit 42). No statistically significant differences were seen for any of the other secondary outcomes. The treatment effect varied little by the reason the woman was at risk of preterm birth, the gestational age at which magnesium sulphate treatment was given, the total dose received, or whether maintenance therapy was used. A limitation of the study was that not all trials could provide the data required for the planned analyses so that combined with low event rates for some important clinical events, the power to find a difference was limited. CONCLUSIONS: Antenatal magnesium sulphate given prior to preterm birth for fetal neuroprotection prevents CP and reduces the combined risk of fetal/infant death or CP. Benefit is seen regardless of the reason for preterm birth, with similar effects across a range of preterm gestational ages and different treatment regimens. Widespread adoption worldwide of this relatively inexpensive, easy-to-administer treatment would lead to important global health benefits for infants born preterm.
[Mh] Termos MeSH primário: Paralisia Cerebral
Sulfato de Magnésio
Nascimento Prematuro
[Mh] Termos MeSH secundário: Paralisia Cerebral/sangue
Paralisia Cerebral/epidemiologia
Paralisia Cerebral/etiologia
Paralisia Cerebral/prevenção & controle
Relação Dose-Resposta a Droga
Feminino
Sangue Fetal/química
Idade Gestacional
Seres Humanos
Lactente
Mortalidade Infantil
Recém-Nascido
Recém-Nascido Prematuro/sangue
Sulfato de Magnésio/administração & dosagem
Sulfato de Magnésio/sangue
Fármacos Neuroprotetores/administração & dosagem
Fármacos Neuroprotetores/sangue
Avaliação de Processos e Resultados (Cuidados de Saúde)
Gravidez
Nascimento Prematuro/sangue
Nascimento Prematuro/mortalidade
Nascimento Prematuro/fisiopatologia
Nascimento Prematuro/terapia
Cuidado Pré-Natal/métodos
Ensaios Clínicos Controlados Aleatórios como Assunto
Tempo para o Tratamento/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Neuroprotective Agents); 7487-88-9 (Magnesium Sulfate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171022
[Lr] Data última revisão:
171022
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pmed.1002398


  7 / 4534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28922852
[Au] Autor:Daher I; Le Dieu-Lugon B; Dourmap N; Lecuyer M; Ramet L; Gomila C; Ausseil J; Marret S; Leroux P; Roy V; El Mestikawy S; Daumas S; Gonzalez B; Leroux-Nicollet I; Cleren C
[Ad] Endereço:Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, P
[Ti] Título:Magnesium Sulfate Prevents Neurochemical and Long-Term Behavioral Consequences of Neonatal Excitotoxic Lesions: Comparison Between Male and Female Mice.
[So] Source:J Neuropathol Exp Neurol;76(10):883-897, 2017 Oct 01.
[Is] ISSN:1554-6578
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Magnesium sulfate (MgSO4) administration to mothers at risk of preterm delivery is proposed as a neuroprotective strategy against neurological alterations such as cerebral palsy in newborns. However, long-term beneficial or adverse effects of MgSO4 and sex-specific sensitivity remain to be investigated. We conducted behavioral and neurochemical studies of MgSO4 effects in males and females, from the perinatal period to adolescence in a mouse model of cerebral neonatal lesion. The lesion was produced in 5-day-old (P5) pups by ibotenate intracortical injection. MgSO4 (600 mg/kg, i.p.) prior to ibotenate prevented lesion-induced sensorimotor alterations in both sexes at P6 and P7. The lesion increased glutamate level at P10 in the prefrontal cortex, which was prevented by MgSO4 in males. In neonatally lesioned adolescent mice, males exhibited more sequelae than females in motor and cognitive functions. In the perirhinal cortex of adolescent mice, the neonatal lesion induced an increase in vesicular glutamate transporter 1 density in males only, which was negatively correlated with cognitive scores. Long-term sequelae were prevented by neonatal MgSO4 administration. MgSO4 never induced short- or long-term deleterious effect on its own. These results also strongly suggest that sex-specific neuroprotection should be foreseen in preterm infants.
[Mh] Termos MeSH primário: Encéfalo/metabolismo
Bloqueadores dos Canais de Cálcio/administração & dosagem
Transtornos Neurológicos da Marcha/prevenção & controle
Sulfato de Magnésio/administração & dosagem
Síndromes Neurotóxicas/complicações
[Mh] Termos MeSH secundário: Envelhecimento/efeitos dos fármacos
Animais
Animais Recém-Nascidos
Encéfalo/efeitos dos fármacos
Encéfalo/patologia
Bloqueadores dos Canais de Cálcio/sangue
Modelos Animais de Doenças
Agonistas de Aminoácidos Excitatórios/toxicidade
Feminino
Lateralidade Funcional
Transtornos Neurológicos da Marcha/etiologia
Ácido Glutâmico/metabolismo
Ácido Ibotênico/toxicidade
Estudos Longitudinais
Sulfato de Magnésio/sangue
Masculino
Camundongos
Destreza Motora/efeitos dos fármacos
Síndromes Neurotóxicas/etiologia
Síndromes Neurotóxicas/patologia
Fatores Sexuais
Proteína Vesicular 1 de Transporte de Glutamato/metabolismo
Ácido gama-Aminobutírico/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calcium Channel Blockers); 0 (Excitatory Amino Acid Agonists); 0 (Vesicular Glutamate Transport Protein 1); 2552-55-8 (Ibotenic Acid); 3KX376GY7L (Glutamic Acid); 56-12-2 (gamma-Aminobutyric Acid); 7487-88-9 (Magnesium Sulfate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170920
[St] Status:MEDLINE
[do] DOI:10.1093/jnen/nlx073


  8 / 4534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28864226
[Au] Autor:Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
[Ad] Endereço:Department of Pharmacy, Hokkaido University Hospital, Kita 14-jo, Nishi 5-chome, Kita-ku, Sapporo 060-8648, Japan.
[Ti] Título:Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
[So] Source:Life Sci;189:18-22, 2017 Nov 15.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Pretreatment with magnesium (Mg) has been reported to attenuate cisplatin (CDDP)-induced nephrotoxicity (CIN). This attenuation involves modulation of the expression of renal transporters, resulting in reduced renal platinum accumulation after a single round of CDDP treatment. In this study, we investigated whether Mg co-administration ameliorates CIN after multiple doses of CDDP as effectively as after a single dose. METHODS: Rats were divided into control, Mg alone, CDDP alone, and CDDP with Mg groups. Rats received CDDP (2.5mg/kg), MgSO (40mg/kg), or saline once per week for three weeks. Seven days after the third round of treatment, the kidneys were excised, and the expression of renal transporters and renal platinum accumulation were analyzed. RESULTS: CDDP significantly elevated serum creatinine levels, which were significantly reduced by Mg co-administration. Renal platinum accumulation was significantly lower in the CDDP-Mg group than in the CDDP group. Expression of renal organic cation transporter 2 (rOct2) and multidrug and toxin extrusion protein 1 (rMate1), which are involved in CDDP transport, did not differ between the groups. However, the expression of copper transporter 1 (rCtr1) was significantly downregulated after Mg co-administration. CONCLUSION: Mg co-administration significantly attenuated CIN by reducing renal platinum accumulation even after multiple rounds of treatment with CDDP as effectively as in a model of a single CDDP administration. However, the specific underlying mechanism was different between single and multiple administrations, further studies will be needed to identify what contributes to this difference and to elucidate how Mg regulates the expression of renal transporters.
[Mh] Termos MeSH primário: Antineoplásicos/toxicidade
Cisplatino/toxicidade
Nefropatias/prevenção & controle
Sulfato de Magnésio/farmacologia
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/administração & dosagem
Cisplatino/administração & dosagem
Creatinina/sangue
Nefropatias/induzido quimicamente
Sulfato de Magnésio/administração & dosagem
Masculino
Proteínas de Transporte de Cátions Orgânicos/metabolismo
Transportador 2 de Cátion Orgânico
Platina/metabolismo
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Organic Cation Transport Proteins); 0 (Organic Cation Transporter 2); 0 (Slc22a2 protein, rat); 49DFR088MY (Platinum); 7487-88-9 (Magnesium Sulfate); AYI8EX34EU (Creatinine); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170903
[St] Status:MEDLINE


  9 / 4534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28827216
[Au] Autor:Chen Q; Ng V; Warfel JM; Merkel TJ; Stibitz S
[Ad] Endereço:Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA qing.chen@fda.hhs.gov.
[Ti] Título:Activation of Bvg-Repressed Genes in Bordetella pertussis by RisA Requires Cross Talk from Noncooperonic Histidine Kinase RisK.
[So] Source:J Bacteriol;199(22), 2017 Nov 15.
[Is] ISSN:1098-5530
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The two-component response regulator RisA, encoded by open reading frame BP3554 in the Tohama I genomic sequence, is a known activator of genes, a set of genes whose expression is increased under the same environmental conditions (known as modulation) that result in repression of the virulence regulon. Here we demonstrate that RisA is phosphorylated and that RisA phosphorylation is required for activation of genes. An adjacent histidine kinase gene, , is truncated by frameshift mutation in but not in or Neither deletion of ' or nor phenotypic modulation with MgSO affected levels of phosphorylated RisA (RisA∼P) in However, RisA phosphorylation did require the histidine kinase encoded by BP3223, here named RisK (cognate histidine kinase of RisA). RisK was also required for expression of the genes. This requirement could be obviated by the introduction of the phosphorylation-mimicking RisA mutant, indicating that an active conformation of RisA, but not phosphorylation , is crucial for activation. Interestingly, expression of genes is still modulated by MgSO in cells harboring the RisA mutation, suggesting that the activated RisA senses additional signals to control expression in response to environmental stimuli. In , the BvgAS two-component system activates the expression of virulence genes by binding of BvgA∼P to their promoters. Expression of the reciprocally regulated genes requires RisA and is also repressed by the Bvg-activated BvgR. RisA is an OmpR-like response regulator, but RisA phosphorylation was not expected because the gene for its presumed, cooperonic, histidine kinase is inactivated by mutation. In this study, we demonstrate phosphorylation of RisA by a noncooperonic histidine kinase. We also show that RisA phosphorylation is necessary but not sufficient for activation but, importantly, is not affected by BvgAS status. Instead, we propose that expression is controlled by BvgAS through its regulation of BvgR, a cyclic di-GMP (c-di-GMP) phosphodiesterase.
[Mh] Termos MeSH primário: Proteínas de Bactérias/genética
Proteínas de Bactérias/metabolismo
Bordetella pertussis/genética
Regulação Bacteriana da Expressão Gênica
Receptores de Superfície Celular/genética
Receptores de Superfície Celular/metabolismo
Transativadores/metabolismo
[Mh] Termos MeSH secundário: Bordetella bronchiseptica/genética
Bordetella pertussis/metabolismo
Bordetella pertussis/patogenicidade
Mutação da Fase de Leitura
Genes Reguladores
Histidina Quinase/metabolismo
Sulfato de Magnésio/metabolismo
Mutação
Fosforilação
Regiões Promotoras Genéticas
Regulon
Transdução de Sinais
Transativadores/genética
Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Bvg accessory factor protein, Bordetella pertussis); 0 (Receptors, Cell Surface); 0 (RisA protein, Bordetella); 0 (Trans-Activators); 0 (vrg protein, Bordetella pertussis); 7487-88-9 (Magnesium Sulfate); EC 2.7.13.1 (Histidine Kinase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170823
[St] Status:MEDLINE


  10 / 4534 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28797767
[Au] Autor:Dong XY; Bai CB; Nao JF
[Ad] Endereço:Department of Neurology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, China.
[Ti] Título:Clinical and radiological features of posterior reversible encephalopathy syndrome in patients with pre-eclampsia and eclampsia.
[So] Source:Clin Radiol;72(10):887-895, 2017 Oct.
[Is] ISSN:1365-229X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIM: To analyse and summarise clinical and radiological features among patients with posterior reversible encephalopathy syndrome (PRES), to assess related factors with eclampsia and pre-eclampsia, and to compare the different factors between cytotoxic and vasogenic oedema among PRES patients. MATERIALS AND METHODS: The clinical and radiological findings of 237 pre-eclamptic or eclamptic patients with neurological symptoms were evaluated retrospectively. Multiple logistic regression analyses were performed to compare the differences among these parameters. RESULTS: Seventy-six patients (32.07%) were diagnosed with PRES. Multiple logistic regression indicated that seizure (odds ratio [OR], 2.760; 95% confidence interval [CI]: 1.087-7.011; p=0.033), visual disturbances (OR=2.062 95%CI, 1.033-4.115; p=0.004), multiple production history (OR=3.637; 95% CI: 1.068-8.228; p=0.002) were independent risk factors for PRES. PRES+ (OR=3.217; 95%CI, 1.346-7.686; p=0.009), Visual disturbances (OR=4.283; 95% CI: 1.843-9.953; p=0.001) had strong association with eclampsia. Visual disturbances (OR=7.200; 95% CI: 2.116-24.496; p=0.002) had strong correlation with eclampsia among PRES+ patients. Visual disturbances (OR=2.947; 95% CI: 1.135-7.648; p=0.026) were independently related to cytotoxic oedema. CONCLUSIONS: Nearly one-third of pre-eclampsia or eclampsia patients with neurological symptoms have PRES. Visual disturbances, seizure, multiple production history are independent risk factors for PRES. Visual disturbances have a strong association with eclampsia whether patients have PRES or not. Visual disturbances are independently related to cytotoxic oedema among PRES+ patients.
[Mh] Termos MeSH primário: Eclampsia/diagnóstico
Imagem por Ressonância Magnética
Síndrome da Leucoencefalopatia Posterior/diagnóstico por imagem
Pré-Eclâmpsia/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Anticonvulsivantes/uso terapêutico
Anti-Hipertensivos/uso terapêutico
Encéfalo/diagnóstico por imagem
Diazepam/uso terapêutico
Eclampsia/terapia
Feminino
Seres Humanos
Labetalol/uso terapêutico
Sulfato de Magnésio/uso terapêutico
Neuroimagem/métodos
Fenitoína/uso terapêutico
Síndrome da Leucoencefalopatia Posterior/diagnóstico
Síndrome da Leucoencefalopatia Posterior/tratamento farmacológico
Pré-Eclâmpsia/terapia
Gravidez
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticonvulsants); 0 (Antihypertensive Agents); 6158TKW0C5 (Phenytoin); 7487-88-9 (Magnesium Sulfate); Q3JTX2Q7TU (Diazepam); R5H8897N95 (Labetalol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170812
[St] Status:MEDLINE



página 1 de 454 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde